Contract Research and Manufacturing Organisation (CRAMs) have emerged as the key future models, engaging in both contract reseach and
manufacturing. 29% of all manufacturing output is expected to be produced vis third parties by 2010, engaging in both contract research and
manufacturing. Major players like AstraZeneca, Pfizer, Roche, Schering are currently undertaking manufacturing strategy reviews to
enhance profibility. Low cost competition from Asia will be the key influence on contract manufacturing organisation industry over the next
Drug manufacturing now typically accounts for 25% of company costs and achieving agility in the production process has become essential
for pharma companies hoping to align their supply chains with constant shifts in glocal product demand. In addition to offering effeciencies
in cost, capacity and time-to-market , contract manufacturing organisations can provide innovative, state-of-art product and process and
production technologies to support the rapid technical transfer of products from the R&D to commercial manufacturing. However, effective
management of contract manufacturing organisations/sponsor relationships is critical not only in satisfying regulatory requirements amid
growing concerns over the quality control, but also meeting the overall commercial aim of the project.
We at APAC, through our industry contacts, connect customers to the right contract manufacturers in the desired region. This transferring of
technology to a cost effective region can significantly bring down the manufacturing cost, improve return on investment, save time and
regulatory hiccups and enable companies to focus their business on their core competencies which will have a potential impact on its bottom
line. The work involves extreme analysis and research into identifying the prospective players from the desired region, determining the
feasibility and getting the other side participate into an operation like that, taking care of legal formalities and every other minuscule.